Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial. (Q50587480)

From Wikidata

Jump to navigation Jump to search

scientific article published in August 1999

Language	Label	Description	Also known as
English	Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial.	scientific article published in August 1999

Statements

scholarly article

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/10460040

Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial. (English)

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/10460040

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

author name string

G Barbaro

1

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/10460040

G Di Lorenzo

2

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/10460040

G Belloni

3

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/10460040

L Ferrari

4

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/10460040

A Paiano

5

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/10460040

P Del Poggio

6

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/10460040

D Bacca

7

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/10460040

L Fruttaldo

8

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/10460040

F Mongiò

9

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/10460040

R Francavilla

10

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/10460040

G Scotto

11

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/10460040

B Grisorio

12

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/10460040

G Calleri

13

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/10460040

M Annese

14

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/10460040

A Barelli

15

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/10460040

P Rocchetto

16

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/10460040

G Rizzo

17

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/10460040

G Gualandi

18

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/10460040

I Poltronieri

19

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/10460040

G Barbarini

20

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/10460040

language of work or name

0 references

publication date

1 August 1999

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/10460040

American Journal of Medicine

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/10460040

107

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/10460040

2

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/10460040

112-118

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/10460040

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900160-6

7 January 2021

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900160-6

7 January 2021

A randomized controlled open study of interferon alpha-2b treatment of chronic non-A, non-B posttransfusion hepatitis: no correlation of outcome to presence of hepatitis C virus antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900160-6

7 January 2021

Interferon for non-A, non-B chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900160-6

7 January 2021

Ribavirin treatment for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900160-6

7 January 2021

A pilot study of ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900160-6

7 January 2021

Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900160-6

7 January 2021

Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900160-6

7 January 2021

A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900160-6

7 January 2021

Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900160-6

7 January 2021

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900160-6

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900160-6

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900160-6

7 January 2021

Decrease in Serum Hepatitis C Viral RNA during Alpha-Interferon Therapy for Chronic Hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900160-6

7 January 2021

Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900160-6

7 January 2021

Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900160-6

7 January 2021

The entire nucleotide sequence and classification of a hepatitis C virus isolate of a novel genotype from an Indonesian patient with chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900160-6

7 January 2021

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900160-6

7 January 2021

Combined interferon-alpha 2, rimantadine hydrochloride, and ribavirin inhibition of influenza virus replication in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900160-6

7 January 2021

Interferon-ribavirin combination therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900160-6

7 January 2021

Molecular mechanisms of action of ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900160-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0002-9343(99)00160-6

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/10460040

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/10460040

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50587480&oldid=1590370943"